Copy Link Print Information

(R)-CCG-1423

15 Cited Publications
Customer Review

Based on 15 publication(s) in Google Scholar

(R)-CCG-1423 is an inhibitor of RhoA. (R)-CCG-1423 inhibits downstream of Rho and shows specificity for SRE.

For research use only. We do not sell to patients.

  • CAS No.: 2309931-09-5
  • Formula: C18H13ClF6N2O3
  • Molecular Weight:454.75
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • (R)-CCG-1423 Chemical Structure
    (R)-CCG-1423 Chemical Structure
  • Experimental Validation Results for (R)-CCG-1423
  • Experimental Validation Results for (R)-CCG-1423
  • Experimental Validation Results for (R)-CCG-1423
  • Experimental Validation Results for (R)-CCG-1423
  • Experimental Validation Results for (R)-CCG-1423
  • Experimental Validation Results for (R)-CCG-1423
CAS No.: 2309931-09-5
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of (R)-CCG-1423:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) (R)-CCG-1423

More
Customer Validation & Images
IFHistological Imaging/StainingWBBio/Physico-chemical AssayELISA
  • Histological Imaging/Staining
  • WB
  • Bio/Physico-chemical Assay
  • IF
  • ELISA
  • WB

All Ras Isoforms

More

All Akt Isoforms

More

All PI3K Isoforms

More
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • (R)-CCG-1423 Chemical Structure
    (R)-CCG-1423 Chemical Structure
    1/16
  • 1/16

    (R)-CCG-1423 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2026 Mar:90:104049. [Abstract]

    Customer Validation
     Representative images of HE and Oil Red O staining of cross-sections of aortic roots in mice with the indicated groups (scale bar, 200 μm; n = 7). H&E and Oil Red O staining of the aortic roots in high-cholesterol diet-fed Apoe−/− mice also demonstrated that CCG-1423 (1 mg/kg; i.p.; once daily for the first 4 weeks and every other day for the subsequent 4 weeks) significantly reduced plaque size and lipid content.

  • 1/16

    (R)-CCG-1423 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2026 Mar:90:104049. [Abstract]

    Customer Validation
     Western blot analysis of ITGB2 levels in mouse aortic plaques of mice in indicated groups (n = 7). CCG-1423 (1 mg/kg; i.p.; once daily for the first 4 weeks and every other day for the subsequent 4 weeks) was used to verify that MRTFA can regulate the expression of ITGB2 in vivo. Isolation of mouse aortic plaques demonstrated significantly lower ITGB2 expression in the CCG-1423 group relative to the solvent group.

  • 1/16

    (R)-CCG-1423 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2026 Mar:90:104049. [Abstract]

    Customer Validation
     The serum ALT, AST and Cr levels in specific groups of mice (n = 7). CCG-1423 (1 mg/kg; i.p.; once daily for the first 4 weeks and every other day for the subsequent 4 weeks) exhibited no obvious adverse impacts on liver and kidney function in mice, as no significant intergroup differences were detected in serum ALT, AST, and creatinine levels in high-cholesterol diet-fed Apoe−/− mice.

  • 1/16

    (R)-CCG-1423 purchased from MedChemExpress. Usage Cited in: Exp Mol Med. 2023 May;55(5):898-909. [Abstract]

    Customer Validation
     Effect of CCG-1423 (1 μM; 24 h) on SZ formation in osteoclasts. Cells were treated with CCG-1423 on day 6 and immunostained for F-actin (red, phalloidin) and nuclei (blue, DAPI). Scale bar: 25 μm.

  • 1/16

    (R)-CCG-1423 purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2022 Jun;12(6):e850. [Abstract]

    Customer Validation
     PEMs were treated with RhoA inhibitor (CCG-1423, 20 μM), Cdc42 inhibitor (CASIN, 20 μM), Rac1 inhibitor (1A-116, 10 μM) or dual Cdc42/Rac1 inhibitor (MBQ-167, 10 μM) for 1 h followed by Pam3CSK4 (0.5 μg/ml) and BSA or UGRP1 (0.5 μg/ml) treatment for 9 h to measure IL-6 expression by ELISA (n = 3).

  • 1/16

    (R)-CCG-1423 purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2022 Jun;12(6):e850. [Abstract]

    Customer Validation
     Immunoblot analysis of p65 in the whole cell lysate and nucleus in UGRP1 (0.5 μg/mL) and RhoA inhibitor (CCG-1423, 20 μM) treated PEMs for 6 h followed by Pam3CSK4 (0.5 μg/mL) stimulation for the indicated periods. Tubulin were used as the whole lysate protein control, Lamin‐B served as the nucleic protein control. The results showed that UGRP1-induced enhancement of p65 translocation into the nucleus was suppressed by CCG-1423 after Pam3CSK4 stimulation.

  • (R)-CCG-1423